{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:22:11Z","timestamp":1791649331458,"version":"4.3.4"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00203-026-04788-8","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:48:24Z","timestamp":1773132504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Deploying bacteriophage combinatorial therapy to eradicate resistant Klebsiella pneumoniae UTIs: innovative and personalized phage therapy"],"prefix":"10.1007","volume":"208","author":[{"given":"Usamah","family":"Sayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-5783","authenticated-orcid":false,"given":"Waleed K.","family":"Abdulsahib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael Waleed","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Malathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajashree","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Swarna","family":"Latha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipasha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashna","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigina","family":"Khalikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"4788_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/antibiotics10020124","volume":"10","author":"F Abdelrahman","year":"2021","unstructured":"Abdelrahman F et al (2021) Phage-encoded endolysins. Antibiotics 10:124","journal-title":"Antibiotics"},{"key":"4788_CR2","doi-asserted-by":"crossref","unstructured":"Abed S et al (2025) Genomic insights into halo KS-7: an AI-Driven characterization of a novel. Halophilic Bacteriophage Targeting Carbapenem-Resistant Klebsiella pneumoniae","DOI":"10.21203\/rs.3.rs-6534345\/v1"},{"key":"4788_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/antibiotics8040182","volume":"8","author":"ST Abedon","year":"2019","unstructured":"Abedon ST (2019) Phage-antibiotic combination treatments: antagonistic impacts of antibiotics on the pharmacodynamics of phage therapy? Antibiotics 8:182","journal-title":"Antibiotics"},{"key":"4788_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2174\/138920110790725410","volume":"11","author":"ST Abedon","year":"2010","unstructured":"Abedon ST, Thomas-Abedon C (2010) Phage therapy Pharmacology. Curr Pharm Biotechnol 11:28\u201347","journal-title":"Curr Pharm Biotechnol"},{"key":"4788_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/v10030103","volume":"10","author":"S Ag\u00fan","year":"2018","unstructured":"Ag\u00fan S, Fern\u00e1ndez L, Gonz\u00e1lez-Men\u00e9ndez E, Mart\u00ednez B, Rodr\u00edguez A, Garc\u00eda P (2018) Study of the interactions between bacteriophage phiIPLA-RODI and four chemical disinfectants for the elimination of  Staphylococcus aureus contamination. Viruses 10:103","journal-title":"Viruses"},{"key":"4788_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.20411\/pai.v10i1.777","volume":"10","author":"D Al Ismail","year":"2025","unstructured":"Al Ismail D, Campos-Madueno EI, Don\u00e0 V, Endimiani A (2025) Hypervirulent Klebsiella pneumoniae (hvKp): Overview, epidemiology, and laboratory detection. Pathogens Immun 10:80","journal-title":"Pathogens Immun"},{"key":"4788_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2023.08.009","volume":"83","author":"H Al Lawati","year":"2024","unstructured":"Al Lawati H, Blair BM, Larnard J (2024) Urinary tract infections: core curriculum 2024. Am J Kidney Dis 83:90\u2013100. https:\/\/doi.org\/10.1053\/j.ajkd.2023.08.009","journal-title":"Am J Kidney Dis"},{"key":"4788_CR8","doi-asserted-by":"publisher","unstructured":"Almutairy B (2024) Extensively and multidrug-resistant bacterial strains: case studies of antibiotics resistance. Front Microbiol 15. https:\/\/doi.org\/10.3389\/fmicb.2024.1381511","DOI":"10.3389\/fmicb.2024.1381511"},{"key":"4788_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jgar.2019.09.018","volume":"21","author":"T Anand","year":"2020","unstructured":"Anand T et al (2020a) Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model. J Global Antimicrob Resist 21:34\u201341","journal-title":"J Global Antimicrob Resist"},{"key":"4788_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jgar.2019.09.018","volume":"21","author":"T Anand","year":"2020","unstructured":"Anand T et al (2020b) Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model. J Global Antimicrob Resist 21:34\u201341. https:\/\/doi.org\/10.1016\/j.jgar.2019.09.018","journal-title":"J Global Antimicrob Resist"},{"key":"4788_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12866-025-04101-5","volume":"25","author":"EE Asare Yeboah","year":"2025","unstructured":"Asare Yeboah EE et al (2025) Whole-Genome sequencing and bioinformatics analysis of ESBL-producing Klebsiella pneumoniae in a Ghanaian teaching hospital. BMC Microbiol 25:401","journal-title":"BMC Microbiol"},{"key":"4788_CR12","doi-asserted-by":"publisher","first-page":"110148","DOI":"10.1016\/j.virol.2024.110148","volume":"597","author":"S Asgharzadeh Kangachar","year":"2024","unstructured":"Asgharzadeh Kangachar S et al (2024) Discovery and characterisation of new phage targeting uropathogenic  Escherichia coli. Virology 597:110148. https:\/\/doi.org\/10.1016\/j.virol.2024.110148","journal-title":"Virology"},{"key":"4788_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3390\/pathogens14111127","volume":"14","author":"NJ Ayon","year":"2025","unstructured":"Ayon NJ (2025) Bacterial proteomics and antibiotic resistance identification: is Single-Cell analysis a worthwhile pursuit? Pathogens 14:1127","journal-title":"Pathogens"},{"key":"4788_CR14","doi-asserted-by":"crossref","unstructured":"Azeredo J, Sillankorva S (2018) Bacteriophage therapy. Springer","DOI":"10.1007\/978-1-4939-7395-8"},{"key":"4788_CR15","doi-asserted-by":"publisher","first-page":"738223","DOI":"10.3389\/fcimb.2021.738223","volume":"11","author":"V Ball\u00e9n","year":"2021","unstructured":"Ball\u00e9n V, Gabasa Y, Ratia C, Ortega R, Tejero M, Soto S (2021) Antibiotic resistance and virulence profiles of Klebsiella pneumoniae strains isolated from different clinical sources. Front Cell Infect Microbiol 11:738223","journal-title":"Front Cell Infect Microbiol"},{"key":"4788_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/22221751.2020.1747950","volume":"9","author":"J Bao","year":"2020","unstructured":"Bao J et al (2020) Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae. Emerg Microbes Infect 9:771\u2013774. https:\/\/doi.org\/10.1080\/22221751.2020.1747950","journal-title":"Emerg Microbes Infect"},{"key":"4788_CR17","doi-asserted-by":"publisher","unstructured":"Bilsen MP et al (2023) Definitions of urinary tract infection in current research: A systematic review. Open Forum Infect Dis 10. https:\/\/doi.org\/10.1093\/ofid\/ofad332","DOI":"10.1093\/ofid\/ofad332"},{"key":"4788_CR18","first-page":"186","volume":"5","author":"SK Biswas","year":"2024","unstructured":"Biswas SK et al (2024) Beyond antibiotics: exploring the potential of bacteriophages and phage therapy. PHAGE 5:186\u2013202","journal-title":"PHAGE"},{"key":"4788_CR19","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1093\/jac\/dkaf360","volume":"80","author":"T Blanco-Mart\u00edn","year":"2025","unstructured":"Blanco-Mart\u00edn T et al (2025) Mechanisms of resistance to ceftazidime\/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes. J Antimicrob Chemother 80:3265\u20133272","journal-title":"J Antimicrob Chemother"},{"key":"4788_CR20","doi-asserted-by":"crossref","unstructured":"Bleriot I et al. (2024a) \u00abStudies in vitro e in vivoof Phage Therapy Medical Products (PTMPs) targeting clinical strains of Klebsiella pneumoniae belonging to the clone ST512\u00bb. bioRxiv:2024.2011.2020.624559 doi: 10.1101\/2024.11.20.624559","DOI":"10.1101\/2024.11.20.624559"},{"key":"4788_CR21","doi-asserted-by":"publisher","unstructured":"Bleriot I et al (2024b) Improving phage therapy by evasion of phage resistance mechanisms. JAC-Antimicrobial Resist 6. https:\/\/doi.org\/10.1093\/jacamr\/dlae017","DOI":"10.1093\/jacamr\/dlae017"},{"key":"4788_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/mmi.14134","volume":"110","author":"SS Broendum","year":"2018","unstructured":"Broendum SS, Buckle AM, McGowan S (2018) Catalytic diversity and cell wall binding repeats in the phage-encoded endolysins. Mol Microbiol 110:879\u2013896","journal-title":"Mol Microbiol"},{"key":"4788_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/v11030241","volume":"11","author":"BH Burrowes","year":"2019","unstructured":"Burrowes BH, Molineux IJ, Fralick JA (2019) Directed in vitro evolution of therapeutic bacteriophages: the appelmans protocol. Viruses 11:241","journal-title":"Viruses"},{"key":"4788_CR24","unstructured":"Cai C (2025) Artificial intelligence models for risk analysis of Carbapenem-Resistant Klebsiella pneumoniae: A comparative performance analysis towards logistic regression. Murdoch University"},{"key":"4788_CR25","doi-asserted-by":"publisher","first-page":"38249","DOI":"10.1038\/s41598-025-22075-2","volume":"15","author":"PY Camejo","year":"2025","unstructured":"Camejo PY et al (2025) A machine learning approach to predict strain-specific phage-host interactions. Sci Rep 15:38249","journal-title":"Sci Rep"},{"key":"4788_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-0711-13-16","volume":"13","author":"X Cao","year":"2014","unstructured":"Cao X, Xu X, Zhang Z, Shen H, Chen J, Zhang K (2014) Molecular characterization of clinical multidrug-resistant Klebsiella pneumoniae isolates. Ann Clin Microbiol Antimicrob 13:1\u20135","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"4788_CR26","doi-asserted-by":"crossref","unstructured":"Cao F et al (2015) Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. BioMed Research International 2015:752930","DOI":"10.1155\/2015\/752930"},{"key":"4788_CR28","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.burns.2017.03.029","volume":"43","author":"P Chadha","year":"2017","unstructured":"Chadha P, Katare OP, Chhibber S (2017) Liposome loaded phage cocktail: enhanced therapeutic potential in resolving Klebsiella pneumoniae mediated burn wound infections. Burns 43:1532\u20131543. https:\/\/doi.org\/10.1016\/j.burns.2017.03.029","journal-title":"Burns"},{"key":"4788_CR29","doi-asserted-by":"crossref","unstructured":"Chan BK et al (2025) Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis. Nature medicine:1\u20138","DOI":"10.1038\/s41591-025-03678-8"},{"key":"4788_CR30","doi-asserted-by":"crossref","unstructured":"Chaudhary N et al (2025a) In Vitro and In Vivo Evaluation of Phage-Antibiotic Synergy for the Treatment of Urinary Tract Infections. Microbial Pathogenesis:108005","DOI":"10.1016\/j.micpath.2025.108005"},{"key":"4788_CR31","doi-asserted-by":"publisher","first-page":"100771","DOI":"10.1016\/j.ijmmb.2024.100771","volume":"53","author":"N Chaudhary","year":"2025","unstructured":"Chaudhary N, Sharma K, Kaur H, Prajapati S, Mohan B, Taneja N (2025b) CRISPR-Cas-assisted phage engineering for personalized antibacterial treatments. Ind J Med Microbiol 53:100771","journal-title":"Ind J Med Microbiol"},{"key":"4788_CR34","doi-asserted-by":"publisher","unstructured":"Chen Y, Batra H, Dong J, Chen C, Rao VB, Tao P (2019) Genetic engineering of bacteriophages against infectious diseases. Front Microbiol 10. https:\/\/doi.org\/10.3389\/fmicb.2019.00954","DOI":"10.3389\/fmicb.2019.00954"},{"key":"4788_CR33","doi-asserted-by":"publisher","first-page":"198750","DOI":"10.1016\/j.virusres.2022.198750","volume":"314","author":"X Chen","year":"2022","unstructured":"Chen X et al (2022) Isolation, characterization, and genome analysis of bacteriophage P929 that could specifically lyase the KL19 capsular type of Klebsiella pneumoniae. Virus Res 314:198750. https:\/\/doi.org\/10.1016\/j.virusres.2022.198750","journal-title":"Virus Res"},{"key":"4788_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41522-024-00603-8","volume":"10","author":"H Chen","year":"2024","unstructured":"Chen H et al (2024) A Klebsiella-phage cocktail to broaden the host range and delay bacteriophage resistance both in vitro and in vivo. Npj Biofilms Microbiomes 10:127. https:\/\/doi.org\/10.1038\/s41522-024-00603-8","journal-title":"Npj Biofilms Microbiomes"},{"key":"4788_CR35","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3390\/antibiotics13090870","volume":"13","author":"L Cui","year":"2024","unstructured":"Cui L et al (2024) A comprehensive review on phage therapy and phage-Based drug development. Antibiotics 13:870","journal-title":"Antibiotics"},{"key":"4788_CR36","doi-asserted-by":"publisher","first-page":"1691215","DOI":"10.3389\/fcimb.2025.1691215","volume":"15","author":"JD DING","year":"2025","unstructured":"DING JD, Liao C, Yan W, Ma M, Rui Z, Jiang L (2025) Combating Klebsiella pneumoniae: from antimicrobial resistance mechanisms to phage-based combination therapies. Front Cell Infect Microbiol 15:1691215","journal-title":"Front Cell Infect Microbiol"},{"key":"4788_CR37","doi-asserted-by":"crossref","unstructured":"Dorta-Gorr\u00edn A, Salgueiri\u00f1o V, Hevia LG (2025) Nanomedicine for phage therapy: encapsulation strategies for enhanced antimicrobial efficacy. Int J Antimicrob Agents :107660","DOI":"10.1016\/j.ijantimicag.2025.107660"},{"key":"4788_CR38","doi-asserted-by":"publisher","first-page":"1611857","DOI":"10.3389\/fcimb.2025.1611857","volume":"15","author":"MB Doud","year":"2025","unstructured":"Doud MB, Robertson JM, Strathdee SA (2025) Optimizing phage therapy with artificial intelligence: a perspective. Front Cell Infect Microbiol 15:1611857","journal-title":"Front Cell Infect Microbiol"},{"key":"4788_CR39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/antibiotics13020195","volume":"13","author":"J Duarte","year":"2024","unstructured":"Duarte J et al (2024) Potential of an isolated bacteriophage to inactivate Klebsiella pneumoniae: preliminary studies to control urinary tract infections. Antibiotics 13:195","journal-title":"Antibiotics"},{"key":"4788_CR40","doi-asserted-by":"crossref","unstructured":"Dunne M, Perepanova TS, Bjerklund Johansen, Truls E.north_eastCai, Tommaso (2024) Bacteriophage therapy for urinary tract infections. In: Guide to antibiotics in urology. Springer, pp 189\u2013205","DOI":"10.1007\/978-3-319-92366-6_15"},{"key":"4788_CR41","doi-asserted-by":"publisher","first-page":"13048","DOI":"10.1038\/s41598-022-17275-z","volume":"12","author":"DM El-Atrees","year":"2022","unstructured":"El-Atrees DM, El-Kased RF, Abbas AM, Yassien MA (2022) Characterization and anti-biofilm activity of bacteriophages against urinary tract  Enterococcus faecalis faecalis isolates. Sci Rep 12:13048. https:\/\/doi.org\/10.1038\/s41598-022-17275-z","journal-title":"Sci Rep"},{"key":"4788_CR42","doi-asserted-by":"publisher","unstructured":"El-Demerdash AS, Alfaraj R, Farid FA, Yassin MH, Saleh AM, Dawwam GE (2024) Essential oils as capsule disruptors: enhancing antibiotic efficacy against multidrug-resistant Klebsiella pneumoniae. Front Microbiol 15. https:\/\/doi.org\/10.3389\/fmicb.2024.1467460","DOI":"10.3389\/fmicb.2024.1467460"},{"key":"4788_CR43","doi-asserted-by":"publisher","first-page":"e0151922","DOI":"10.1128\/aac.01519-22","volume":"67","author":"CW Euler","year":"2023","unstructured":"Euler CW et al (2023) PlyKp104, a novel phage lysin for the treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and other Gram-Negative ESKAPE pathogens. Antimicrob Agents Chemother 67:e0151922. https:\/\/doi.org\/10.1128\/aac.01519-22","journal-title":"Antimicrob Agents Chemother"},{"key":"4788_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s42003-022-03001-y","volume":"5","author":"Q Fang","year":"2022","unstructured":"Fang Q, Feng Y, McNally A, Zong Z (2022) Characterization of phage resistance and phages capable of intestinal decolonization of carbapenem-resistant Klebsiella pneumoniae in mice. Commun Biology 5:48. https:\/\/doi.org\/10.1038\/s42003-022-03001-y","journal-title":"Commun Biology"},{"key":"4788_CR45","doi-asserted-by":"publisher","first-page":"1713471","DOI":"10.3389\/fphar.2025.1713471","volume":"16","author":"A Fukaya-Shiba","year":"2025","unstructured":"Fukaya-Shiba A et al (2025) Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections. Front Pharmacol 16:1713471","journal-title":"Front Pharmacol"},{"key":"4788_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12985-024-02450-7","volume":"21","author":"O Gholizadeh","year":"2024","unstructured":"Gholizadeh O, Ghaleh HEG, Tat M, Ranjbar R, Dorostkar R (2024) The potential use of bacteriophages as antibacterial agents against Klebsiella pneumoniae. Virol J 21:191. https:\/\/doi.org\/10.1186\/s12985-024-02450-7","journal-title":"Virol J"},{"key":"4788_CR47","doi-asserted-by":"publisher","first-page":"107275","DOI":"10.1016\/j.ijantimicag.2024.107275","volume":"64","author":"X Han","year":"2024","unstructured":"Han X et al (2024) Clinical and laboratory insights into the threat of hypervirulent Klebsiella pneumoniae. Int J Antimicrob Agents 64:107275. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107275","journal-title":"Int J Antimicrob Agents"},{"key":"4788_CR48","doi-asserted-by":"publisher","unstructured":"Hayakawa K et al (2025) A feasibility study for personalized phage therapy against drug-resistant bacteria in Japan. J Infect Chemother 31:102770. https:\/\/doi.org\/10.1016\/j.jiac.2025.102770","DOI":"10.1016\/j.jiac.2025.102770"},{"key":"4788_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4161\/bact.21440","volume":"2","author":"M Henry","year":"2012","unstructured":"Henry M et al (2012) Development of a high throughput assay for indirectly measuring phage growth using the omnilogtm system. Bacteriophage 2:159\u2013167","journal-title":"Bacteriophage"},{"key":"4788_CR50","doi-asserted-by":"publisher","first-page":"101128mbio00034","DOI":"10.1128\/mBio.00034-21","volume":"12","author":"S Hesse","year":"2021","unstructured":"Hesse S et al (2021) Bacteriophage treatment rescues mice infected with multidrug-resistant Klebsiella pneumoniae ST258. MBio 12:101128mbio00034\u2013101128mbio00021","journal-title":"MBio"},{"key":"4788_CR51","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/v15041020","volume":"15","author":"NM Hitchcock","year":"2023","unstructured":"Hitchcock NM et al (2023) Current clinical landscape and global potential of bacteriophage therapy. Viruses 15:1020","journal-title":"Viruses"},{"key":"4788_CR52","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12985-024-02510-y","volume":"21","author":"M Hosseini Hooshiar","year":"2024","unstructured":"Hosseini Hooshiar M et al (2024) The potential use of bacteriophages as antibacterial agents in dental infection. Virol J 21:258","journal-title":"Virol J"},{"key":"4788_CR53","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12866-025-03903-x","volume":"25","author":"AH Hussein","year":"2025","unstructured":"Hussein AH, Makky S, Hager R, Connerton IF, El-Shibiny A (2025) Characterization and therapeutic potential of phage vB_Eco_ZCEC08 against multidrug-resistant uropathogenic  Escherichia coli. BMC Microbiol 25:221","journal-title":"BMC Microbiol"},{"key":"4788_CR54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12985-024-02306-0","volume":"21","author":"NM Ismael","year":"2024","unstructured":"Ismael NM, Azzam M, Abdelmoteleb M, El-Shibiny A (2024) Phage vB_Ec_ZCEC14 to treat antibiotic-resistant Escherichia coli isolated from urinary tract infections. Virol J 21:44. https:\/\/doi.org\/10.1186\/s12985-024-02306-0","journal-title":"Virol J"},{"key":"4788_CR55","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/10766294251375937","volume":"31","author":"N Javan","year":"2025","unstructured":"Javan N, Ghotaslou R, Samadi Kafil H, Memar MY, Sadeghi J, Ghotaslou P (2025) Overcoming Multi-Drug-Resistant Klebsiella pneumoniae infections. Microb Drug Resist 31:323\u2013337","journal-title":"Microb Drug Resist"},{"key":"4788_CR56","doi-asserted-by":"publisher","unstructured":"Kan L, Barr JJ (2023) A Mammalian Cell\u2019s Guide on How to Process a Bacteriophage.Annual Review of Virology 10:183\u2013198 doi: https:\/\/doi.org\/10.1146\/annurev-virology-111821-111322","DOI":"10.1146\/annurev-virology-111821-111322"},{"key":"4788_CR57","doi-asserted-by":"publisher","first-page":"110148","DOI":"10.1016\/j.virol.2024.110148","volume":"597","author":"SA Kangachar","year":"2024","unstructured":"Kangachar SA et al (2024) Discovery and characterisation of new phage targeting uropathogenic Escherichia coli. Virology 597:110148","journal-title":"Virology"},{"key":"4788_CR58","doi-asserted-by":"publisher","first-page":"1588472","DOI":"10.3389\/fmicb.2025.1588472","volume":"16","author":"C Karthika","year":"2025","unstructured":"Karthika C, Malligarjunan N, Hari Prasath N, Karutha Pandian S, Gowrishankar S (2025) Phage (cocktail)-antibiotic synergism: a new frontier in addressing Klebsiella pneumoniae resistance. Front Microbiol 16:1588472","journal-title":"Front Microbiol"},{"key":"4788_CR59","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1038\/s41598-024-53130-z","volume":"14","author":"JN Kaur","year":"2024","unstructured":"Kaur JN et al (2024) Next generation antibiotic combinations to combat pan-drug resistant Klebsiella pneumoniae. Sci Rep 14:3148","journal-title":"Sci Rep"},{"key":"4788_CR60","doi-asserted-by":"crossref","unstructured":"Keith M et al (2024) Predictive phage therapy for Escherichia coli urinary tract infections: Cocktail selection for therapy based on machine learning models. Proceedings of the National Academy of Sciences 121:e2313574121","DOI":"10.1073\/pnas.2313574121"},{"key":"4788_CR61","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jgar.2024.01.018","volume":"36","author":"FZ Kelishomi","year":"2024","unstructured":"Kelishomi FZ et al (2024) Evaluation of the therapeutic effect of a novel bacteriophage in the healing process of infected wounds with Klebsiella pneumoniae in mice. J Global Antimicrob Resist 36:371\u2013378. https:\/\/doi.org\/10.1016\/j.jgar.2024.01.018","journal-title":"J Global Antimicrob Resist"},{"key":"4788_CR62","doi-asserted-by":"publisher","first-page":"e00889","DOI":"10.1128\/spectrum.00889-23","volume":"11","author":"P Khunti","year":"2023","unstructured":"Khunti P et al (2023) A novel coli myophage and antibiotics synergistically inhibit the growth of the uropathogenic E. coli strain CFT073 in stoichiometric niches. Microbiol Spectr 11:e00889\u2013e00823. https:\/\/doi.org\/10.1128\/spectrum.00889-23","journal-title":"Microbiol Spectr"},{"key":"4788_CR63","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(24)00424-9","volume":"24","author":"P Kim","year":"2024","unstructured":"Kim P et al (2024) Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to <\u2009em>Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. Lancet Infect Dis 24:1319\u20131332. https:\/\/doi.org\/10.1016\/S1473-3099(24)00424-9","journal-title":"Lancet Infect Dis"},{"key":"4788_CR64","doi-asserted-by":"crossref","unstructured":"Ko S, Kim J, Cho J-H, Kim Y, Kim D (2025) Deep learning-guided structural analysis of a novel bacteriophage KPP105 against multidrug-resistant Klebsiella pneumoniae. Computational and Structural Biotechnology Journal","DOI":"10.1016\/j.csbj.2025.04.032"},{"key":"4788_CR65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13756-023-01282-4","volume":"12","author":"SWC Koh","year":"2023","unstructured":"Koh SWC et al (2023) Antibiotic treatment failure of uncomplicated urinary tract infections in primary care. Antimicrob Resist Infect Control 12:73","journal-title":"Antimicrob Resist Infect Control"},{"key":"4788_CR66","doi-asserted-by":"publisher","first-page":"e01353","DOI":"10.1128\/aem.01353-24","volume":"90","author":"X Kou","year":"2024","unstructured":"Kou X, Yang X, Zheng R (2024) Challenges and opportunities of phage therapy for Klebsiella pneumoniae infections. Appl Environ Microbiol 90:e01353\u2013e01324","journal-title":"Appl Environ Microbiol"},{"key":"4788_CR67","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrmicro2315","volume":"8","author":"SJ Labrie","year":"2010","unstructured":"Labrie SJ, Samson JE, Moineau S (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317\u2013327","journal-title":"Nat Rev Microbiol"},{"key":"4788_CR68","doi-asserted-by":"publisher","unstructured":"Lafor\u00eat F et al (2022) In vitro and in vivo assessments of two newly isolated bacteriophages against an ST13 urinary tract infection Klebsiella pneumoniae. Viruses 14. https:\/\/doi.org\/10.3390\/v14051079","DOI":"10.3390\/v14051079"},{"key":"4788_CR70","doi-asserted-by":"publisher","first-page":"e0003723","DOI":"10.1128\/aac.00037-23","volume":"67","author":"T Le","year":"2023","unstructured":"Le T et al (2023) Therapeutic potential of intravenous phage as standalone therapy for recurrent Drug-Resistant urinary tract infections. Antimicrob Agents Chemother 67:e0003723. https:\/\/doi.org\/10.1128\/aac.00037-23","journal-title":"Antimicrob Agents Chemother"},{"key":"4788_CR69","doi-asserted-by":"publisher","first-page":"e1012971","DOI":"10.1371\/journal.ppat.1012971","volume":"21","author":"J Le Bris","year":"2025","unstructured":"Le Bris J, Chen N, Supandy A, Rendueles O, Van Tyne D (2025) Phage therapy for  Klebsiella pneumoniae: understanding bacteria\u2013phage interactions for therapeutic innovations. PLoS Pathog 21:e1012971","journal-title":"PLoS Pathog"},{"key":"4788_CR71","doi-asserted-by":"publisher","first-page":"e00449","DOI":"10.1128\/aac.00449-23","volume":"67","author":"JR Lee","year":"2023","unstructured":"Lee JR, Satlin MJ (2023) Case commentary: unlocking the potential of bacteriophage to prevent recurrent urinary tract infections after kidney transplantation. Antimicrob Agents Chemother 67:e00449\u2013e00423. https:\/\/doi.org\/10.1128\/aac.00449-23","journal-title":"Antimicrob Agents Chemother"},{"key":"4788_CR72","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.euf.2024.07.006","volume":"10","author":"L Leitner","year":"2024","unstructured":"Leitner L, Kessler TM, McCallin SE (2024) Innovations in phage therapy for urinary tract infection. Eur Urol Focus 10:722\u2013725","journal-title":"Eur Urol Focus"},{"key":"4788_CR73","doi-asserted-by":"publisher","unstructured":"Letarov AV, Kulikov EE (2018) Determination of the bacteriophage host range: culture-based approach. Bacteriophage Therapy: Lab Clin Pract, pp 75\u201384https:\/\/doi.org\/10.1007\/978-1-4939-7395-8_7","DOI":"10.1007\/978-1-4939-7395-8_7"},{"key":"4788_CR74","doi-asserted-by":"crossref","unstructured":"Letkiewicz S, \u0141usiak-Szelachowska M, Mi\u0119dzybrodzki R, \u017baczek M, Weber-D\u0105browska B, G\u00f3rski A (2021) Low immunogenicity of intravesical phage therapy for urogenitary tract infections. Antibiotics 10:627","DOI":"10.3390\/antibiotics10060627"},{"key":"4788_CR77","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.7150\/ijbs.60551","volume":"17","author":"X Li","year":"2021","unstructured":"Li X et al (2021) A combination therapy of phages and antibiotics: two is better than one. Int J Biol Sci 17:3573","journal-title":"Int J Biol Sci"},{"key":"4788_CR75","doi-asserted-by":"publisher","unstructured":"Li J et al (2023) Development of phage resistance in multidrug-resistant Klebsiella pneumoniae is associated with reduced virulence: a case report of a personalised phage therapy. Clin Microbiol Infect 29:1601.e1601-1601.e1607. https:\/\/doi.org\/10.1016\/j.cmi.2023.08.022","DOI":"10.1016\/j.cmi.2023.08.022"},{"key":"4788_CR78","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2147\/IDR.S453025","volume":"17","author":"Y Li","year":"2024","unstructured":"Li Y, Kumar S, Zhang L (2024) Mechanisms of antibiotic resistance and developments in therapeutic strategies to combat  Klebsiella pneumoniae infection. Infect Drug Resist 17:1107\u20131119. https:\/\/doi.org\/10.2147\/IDR.S453025","journal-title":"Infect Drug Resist"},{"key":"4788_CR76","doi-asserted-by":"crossref","unstructured":"Li N et al (2025) Personalized bacteriophage therapy for chronic biliary tract Pseudomonas aeruginosa infections. hLife","DOI":"10.1016\/j.hlife.2025.03.004"},{"key":"4788_CR79","unstructured":"Liang Q, Liu L (2025) Targeting multidrug-resistant pneumonia: the potential of combined antibiotic therapies and non-antimicrobial approaches. Pak J Pharm Sci 38 2025 Nov-Dec;38(6):2061-2073https:\/\/pubmed.ncbi.nlm.nih.gov\/41139254\/"},{"key":"4788_CR80","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/antibiotics14100997","volume":"14","author":"E Machado","year":"2025","unstructured":"Machado E, Sousa JC (2025) New antibiotics for treating infections caused by Multidrug-Resistant bacteria. Antibiotics 14:997","journal-title":"Antibiotics"},{"key":"4788_CR81","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s00253-018-8811-1","volume":"102","author":"B Maciejewska","year":"2018","unstructured":"Maciejewska B, Olszak T, Drulis-Kawa Z (2018) Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application? Appl Microbiol Biotechnol 102:2563\u20132581","journal-title":"Appl Microbiol Biotechnol"},{"key":"4788_CR82","doi-asserted-by":"publisher","first-page":"e01329","DOI":"10.1128\/mbio.01329-23","volume":"14","author":"B Maciejewska","year":"2023","unstructured":"Maciejewska B et al (2023) Klebsiella phage KP34gp57 capsular depolymerase structure and function: from a serendipitous finding to the design of active mini-enzymes against  K. pneumoniae. MBio 14:e01329\u2013e01323","journal-title":"MBio"},{"key":"4788_CR83","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3390\/pharmaceutics17070820","volume":"17","author":"AN Mafe","year":"2025","unstructured":"Mafe AN, B\u00fcsselberg D (2025) Phage therapy in managing Multidrug-Resistant (MDR) infections in cancer therapy: innovations, complications, and future directions. Pharmaceutics 17:820","journal-title":"Pharmaceutics"},{"key":"4788_CR84","doi-asserted-by":"publisher","first-page":"7723","DOI":"10.1111\/1462-2920.15476","volume":"23","author":"G Majkowska-Skrobek","year":"2021","unstructured":"Majkowska-Skrobek G, Markwitz P, Sosnowska E, Lood C, Lavigne R, Drulis-Kawa Z (2021) The evolutionary trade-offs in phage-resistant entail cross-phage sensitization and loss of multidrug resistance. Environ Microbiol 23:7723\u20137740. https:\/\/doi.org\/10.1111\/1462-2920.15476","journal-title":"Environ Microbiol"},{"key":"4788_CR85","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3390\/pathogens12040623","volume":"12","author":"G Mancuso","year":"2023","unstructured":"Mancuso G, Midiri A, Gerace E, Marra M, Zummo S, Biondo C (2023) Urinary tract infections: the current scenario and future prospects. Pathogens 12:623","journal-title":"Pathogens"},{"key":"4788_CR86","doi-asserted-by":"publisher","unstructured":"Manohar P, Tamhankar AJ, Lundborg CS, Nachimuthu R (2019) Therapeutic characterization and efficacy of bacteriophage cocktails infecting Escherichia coli, Klebsiella pneumoniae, and Enterobacter species. Front Microbiol 10. https:\/\/doi.org\/10.3389\/fmicb.2019.00574","DOI":"10.3389\/fmicb.2019.00574"},{"key":"4788_CR87","first-page":"1011","volume":"14","author":"A Marino","year":"2025","unstructured":"Marino A et al (2025) Phage to ESKAPE: personalizing therapy for MDR Infections\u2014A comprehensive clinical review. Pathogens 14:1011","journal-title":"Compr Clin Rev Pathogens"},{"key":"4788_CR88","doi-asserted-by":"crossref","unstructured":"Marshall MS (1925) Observations on D\u2019Herelle\u2019s Bacteriophage\u2026 Max S. Marshall","DOI":"10.1093\/infdis\/37.2.126"},{"key":"4788_CR89","doi-asserted-by":"publisher","first-page":"155306","DOI":"10.1016\/j.jcrc.2025.155306","volume":"91","author":"I Martin-Loeches","year":"2026","unstructured":"Martin-Loeches I, Torres A, Roquilly A (2026) Hospital-acquired pneumonia: Past, present, and perspectives. J Crit Care 91:155306","journal-title":"J Crit Care"},{"key":"4788_CR90","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.3390\/microorganisms12091795","volume":"12","author":"I Martinho","year":"2024","unstructured":"Martinho I et al (2024a) The potential of phage treatment to inactivate planktonic and biofilm-forming Pseudomonas aeruginosa. Microorganisms 12:1795","journal-title":"Microorganisms"},{"key":"4788_CR91","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.3390\/microorganisms12091795","volume":"12","author":"I Martinho","year":"2024","unstructured":"Martinho I et al (2024b) The potential of phage treatment to inactivate planktonic and Biofilm-Forming Pseudomonas aeruginosa. Microorganisms 12:1795","journal-title":"Microorganisms"},{"key":"4788_CR92","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/22221751.2022.2051752","volume":"11","author":"WMBS Martins","year":"2022","unstructured":"Martins WMBS et al (2022) Effective phage cocktail to combat the rising incidence of extensively drug-resistant  Klebsiella pneumoniae sequence type 16. Emerg Microbes Infections 11:1015\u20131023. https:\/\/doi.org\/10.1080\/22221751.2022.2051752","journal-title":"Emerg Microbes Infections"},{"key":"4788_CR93","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1038\/s41467-023-39863-x","volume":"14","author":"S Meile","year":"2023","unstructured":"Meile S et al (2023) Engineered reporter phages for detection of Escherichia coli, Enterococcus, and Klebsiella in urine. Nat Commun 14:4336","journal-title":"Nat Commun"},{"key":"4788_CR94","doi-asserted-by":"publisher","unstructured":"Melo LDR et al (2016) Development of a phage cocktail to control proteus mirabilis Catheter-associated urinary tract infections. Front Microbiol 7. https:\/\/doi.org\/10.3389\/fmicb.2016.01024","DOI":"10.3389\/fmicb.2016.01024"},{"key":"4788_CR95","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.22092\/ari.2021.356004.1762","volume":"76","author":"B Mijbel Ali","year":"2021","unstructured":"Mijbel Ali B, Gatea Kaabi SA, Al-Bayati MA, Musafer HK (2021) A novel phage cocktail therapy of the urinary tract infection in a mouse model. Arch Razi Inst 76:1229\u20131236. https:\/\/doi.org\/10.22092\/ari.2021.356004.1762","journal-title":"Arch Razi Inst"},{"key":"4788_CR96","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12985-025-02848-x","volume":"22","author":"AA Mohamed","year":"2025","unstructured":"Mohamed AA, El-Zayat EM, El-Shibiny A (2025) Efficacy of phage vB_Ps_ZCPS13 in controlling Pan-drug-resistant Pseudomonas aeruginosa from urinary tract infections (UTIs) and eradicating biofilms from urinary catheters. Virol J 22:236","journal-title":"Virol J"},{"key":"4788_CR97","first-page":"738","volume":"5","author":"NA Mohamed Hassan","year":"2024","unstructured":"Mohamed Hassan NA, Badawy Dawood AH, Sayed SA, Mohamed DH (2024) Distribution, characterization and antibiotic resistance of hypervirulent  Klebsiella pneumoniae (hvKp) strains versus classical strains (CKp) causing healthcare associated infections in Sohag university hospitals. Microbes Infect Dis 5:738\u2013748","journal-title":"Microbes Infect Dis"},{"key":"4788_CR98","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s12223-023-01046-y","volume":"68","author":"M Mohammadi","year":"2023","unstructured":"Mohammadi M, Saffari M, Siadat SD (2023) Phage therapy of antibiotic-resistant strains of  Klebsiella pneumoniae, opportunities and challenges from the past to the future. Folia Microbiol 68:357\u2013368","journal-title":"Folia Microbiol"},{"key":"4788_CR99","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3390\/antibiotics10121508","volume":"10","author":"NA Mohd Asri","year":"2021","unstructured":"Mohd Asri NA et al (2021) Global prevalence of nosocomial multidrug-resistant  Klebsiella pneumoniae: a systematic review and meta-analysis. Antibiotics 10:1508","journal-title":"Antibiotics"},{"key":"4788_CR100","doi-asserted-by":"crossref","unstructured":"Morgan CJ et al (2025) Phage therapy for urinary tract infections: progress and challenges ahead. Int Urogynecol J 36:1\u201311","DOI":"10.1007\/s00192-025-06136-8"},{"key":"4788_CR101","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3389\/fmicb.2018.01696","volume":"9","author":"VV Morozova","year":"2018","unstructured":"Morozova VV, Vlassov VV, Tikunova NV (2018) Applications of bacteriophages in the treatment of localized infections in humans. Front Microbiol 9:1696","journal-title":"Front Microbiol"},{"key":"4788_CR102","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/ph18081115","volume":"18","author":"SK Niazi","year":"2025","unstructured":"Niazi SK (2025) Bacteriophage therapy: discovery, development, and FDA approval pathways. Pharmaceuticals 18:1115","journal-title":"Pharmaceuticals"},{"key":"4788_CR103","doi-asserted-by":"crossref","unstructured":"Okonji KS (2025) Virus meets chemistry: chemical, genomic, and structural strategies for targeted bacteriophage therapeutics","DOI":"10.20944\/preprints202507.2320.v1"},{"key":"4788_CR104","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.3389\/fmicb.2017.02407","volume":"8","author":"A Oliveira","year":"2017","unstructured":"Oliveira A et al (2017) Synergistic antimicrobial interaction between honey and phage against Escherichia coli biofilms. Front Microbiol 8:2407","journal-title":"Front Microbiol"},{"key":"4788_CR105","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3390\/antibiotics14090855","volume":"14","author":"D P\u0103curar","year":"2025","unstructured":"P\u0103curar D, Dinulescu A, Totu A-V, Dijm\u0103rescu I, Pavelescu M-L (2025) Escherichia coli urinary tract infections from a Romanian pediatric hospital: antimicrobial resistance Trends, ESBL Prevalence, and empirical treatment implications. Antibiotics 14:855","journal-title":"Antibiotics"},{"key":"4788_CR106","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3390\/idr16060092","volume":"16","author":"M Palma","year":"2024","unstructured":"Palma M, Qi B (2024) Advancing phage therapy: a comprehensive review of the safety, efficacy, and future prospects for the targeted treatment of bacterial infections. Infect Disease Rep 16:1127","journal-title":"Infect Disease Rep"},{"key":"4788_CR107","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/microorganisms8040542","volume":"8","author":"Q Peng","year":"2020","unstructured":"Peng Q, Fang M, Liu X, Zhang C, Liu Y, Yuan Y (2020) Isolation and characterization of a novel phage for controlling Multidrug-Resistant  Klebsiella pneumoniae. Microorganisms 8:542","journal-title":"Microorganisms"},{"key":"4788_CR108","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.52225\/narra.v3i3.436","volume":"3","author":"MA Perdana","year":"2023","unstructured":"Perdana MA, Wahyuni DD, Yunita R (2023) Characteristics and susceptibility pattern of catheter-associated urinary tract infections (CAUTI) bacteria in indonesia: a study in a National reference hospital of Sumatra region 2020\u20132021. Narra J 3:e436. https:\/\/doi.org\/10.52225\/narra.v3i3.436","journal-title":"Narra J"},{"key":"4788_CR109","doi-asserted-by":"publisher","first-page":"e3002119","DOI":"10.1371\/journal.pbio.3002119","volume":"21","author":"A Petrovic Fabijan","year":"2023","unstructured":"Petrovic Fabijan A, Iredell J, Danis-Wlodarczyk K, Kebriaei R, Abedon ST (2023) Translating phage therapy into the clinic: recent accomplishments but continuing challenges. PLoS Biol 21:e3002119","journal-title":"PLoS Biol"},{"key":"4788_CR110","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/femsre\/fuaa017","volume":"44","author":"DP Pires","year":"2020","unstructured":"Pires DP, Costa AR, Pinto G, Meneses L, Azeredo J (2020) Current challenges and future opportunities of phage therapy. FEMS Microbiol Rev 44:684\u2013700","journal-title":"FEMS Microbiol Rev"},{"key":"4788_CR111","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","volume":"9","author":"J-P Pirnay","year":"2024","unstructured":"Pirnay J-P et al (2024) Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat Microbiol 9:1434\u20131453","journal-title":"Nat Microbiol"},{"key":"4788_CR112","doi-asserted-by":"publisher","first-page":"608402","DOI":"10.3389\/fcimb.2020.608402","volume":"10","author":"J Qin","year":"2021","unstructured":"Qin J et al (2021a) Heterogeneous Klebsiella pneumoniae co-infections complicate personalized bacteriophage therapy. Front Cell Infect Microbiol 10:608402","journal-title":"Front Cell Infect Microbiol"},{"key":"4788_CR113","doi-asserted-by":"publisher","unstructured":"Qin J et al (2021b) Heterogeneous Klebsiella pneumoniae co-infections complicate personalized bacteriophage therapy. Front Cell Infect Microbiol 10. https:\/\/doi.org\/10.3389\/fcimb.2020.608402","DOI":"10.3389\/fcimb.2020.608402"},{"key":"4788_CR114","doi-asserted-by":"publisher","first-page":"145","DOI":"10.33073\/pjm-2010-023","volume":"59","author":"D Rakhuba","year":"2010","unstructured":"Rakhuba D, Kolomiets E, Dey ES, Novik G (2010) Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. Pol J Microbiol 59:145","journal-title":"Pol J Microbiol"},{"key":"4788_CR115","doi-asserted-by":"crossref","unstructured":"Rani R et al (2025) Improved lytic action of engineered phage-encoded endolysin and Docking insights into its action on bacterial peptidoglycan. Int J Biol Macromol, p 320:146105","DOI":"10.1016\/j.ijbiomac.2025.146105"},{"key":"4788_CR116","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1186\/s12879-024-10081-0","volume":"24","author":"S Rastegar","year":"2024","unstructured":"Rastegar S et al (2024) Synergistic effects of bacteriophage cocktail and antibiotics combinations against extensively drug-resistant Acinetobacter baumannii. BMC Infect Dis 24:1208. https:\/\/doi.org\/10.1186\/s12879-024-10081-0","journal-title":"BMC Infect Dis"},{"key":"4788_CR117","doi-asserted-by":"publisher","first-page":"e00089","DOI":"10.1128\/mra.00089-24","volume":"13","author":"M Romance","year":"2024","unstructured":"Romance M, khan MU, Islam MS, Islam MF, Haque MH (2024) Draft genome sequence of multidrug-resistant\u2009Klebsiella pneumoniae Hakim-RU strain isolated from a patient with urinary tract infections in Bangladesh. Microbiol Resource Announcements 13:e00089\u2013e00024. https:\/\/doi.org\/10.1128\/mra.00089-24","journal-title":"Microbiol Resource Announcements"},{"key":"4788_CR118","first-page":"66","volume":"4","author":"T Rose","year":"2014","unstructured":"Rose T et al (2014) Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma 4:66","journal-title":"Int J Burns Trauma"},{"key":"4788_CR119","doi-asserted-by":"publisher","first-page":"e13391","DOI":"10.1111\/tid.13391","volume":"23","author":"OM Rostkowska","year":"2021","unstructured":"Rostkowska OM, Mi\u0119dzybrodzki R, Miszewska-Szyszkowska D, G\u00f3rski A, Durlik M (2021) Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy. Transpl Infect Dis 23:e13391. https:\/\/doi.org\/10.1111\/tid.13391","journal-title":"Transpl Infect Dis"},{"key":"4788_CR120","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2174\/1389201024666221104142457","volume":"24","author":"R Sahu","year":"2023","unstructured":"Sahu R, Singh AK, Kumar A, Singh K, Kumar P (2023) Bacteriophages concept and applications: a review on phage therapy. Curr Pharm Biotechnol 24:1245\u20131264","journal-title":"Curr Pharm Biotechnol"},{"key":"4788_CR121","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11262-024-02052-z","volume":"60","author":"H Salih Do\u011fan","year":"2024","unstructured":"Salih Do\u011fan H, Karaynir A, Yilmaz \u00dc\u0130, Ba\u015fg\u00f6z BB, Ho\u015fbul T, Bozdo\u011fan B (2024) Two novel phages, Klebsiella phage GADU21 and Escherichia phage GADU22, from the urine samples of patients with urinary tract infection. Virus Genes 60:208\u2013221. https:\/\/doi.org\/10.1007\/s11262-024-02052-z","journal-title":"Virus Genes"},{"key":"4788_CR122","doi-asserted-by":"crossref","unstructured":"Saqi HNS, Ameer ASA (2025) Phage therapy for treatment of UTI Caused by multi-drug-resistant E. coli in vitro and in vivo study. Iraqi J Med Sci 23","DOI":"10.22578\/IJMS.23.1.22"},{"key":"4788_CR123","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.mib.2019.03.005","volume":"51","author":"AM Segall","year":"2019","unstructured":"Segall AM, Roach DR, Strathdee SA (2019) Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy. Curr Opin Microbiol 51:46\u201350","journal-title":"Curr Opin Microbiol"},{"key":"4788_CR124","doi-asserted-by":"crossref","unstructured":"Shah AA, Alwashmi AS, Abalkhail A, Alkahtani AM (2025) Emerging challenges in Klebsiella pneumoniae: Antimicrobial resistance and novel approach. Microbial Pathogenesis:107399","DOI":"10.1016\/j.micpath.2025.107399"},{"key":"4788_CR125","doi-asserted-by":"publisher","unstructured":"Shen J, Zhou J, Chen G-Q, Xiu Z-L (2018) Efficient genome engineering of a virulent Klebsiella bacteriophage using CRISPR-Cas9. J Virol 92. https:\/\/doi.org\/10.1128\/jvi00534\u2009\u2013\u200900518","DOI":"10.1128\/jvi"},{"key":"4788_CR126","doi-asserted-by":"publisher","first-page":"108688","DOI":"10.1016\/j.pharmthera.2024.108688","volume":"261","author":"EK Sher","year":"2024","unstructured":"Sher EK et al (2024) Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections. Pharmacol Ther 261:108688. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108688","journal-title":"Pharmacol Ther"},{"key":"4788_CR127","doi-asserted-by":"publisher","first-page":"100515","DOI":"10.1016\/j.ijmmb.2023.100515","volume":"47","author":"S Shree","year":"2024","unstructured":"Shree S, Suman E, Kotian H, Paul SH, M SS (2024) Effect of Klebsiella-specific phage on multidrug-resistant Klebsiella pneumoniae\u2014an experimental study. Ind J Med Microbiol 47:100515. https:\/\/doi.org\/10.1016\/j.ijmmb.2023.100515","journal-title":"Ind J Med Microbiol"},{"key":"4788_CR128","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12887-023-04279-5","volume":"23","author":"RK Shrestha","year":"2023","unstructured":"Shrestha RK et al (2023) Characterization of transferrable mechanisms of quinolone resistance (TMQR) among quinolone-resistant Escherichia coli and Klebsiella pneumoniae causing urinary tract infection in Nepalese children. BMC Pediatr 23:458. https:\/\/doi.org\/10.1186\/s12887-023-04279-5","journal-title":"BMC Pediatr"},{"key":"4788_CR129","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jgar.2024.07.019","volume":"39","author":"AN Singh","year":"2024","unstructured":"Singh AN, Singh A, Nath G (2024a) Evaluation of bacteriophage cocktail on urinary tract infection caused by colistin-resistant  Klebsiella pneumoniae in mice model. J Global Antimicrob Resist 39:41\u201353. https:\/\/doi.org\/10.1016\/j.jgar.2024.07.019","journal-title":"J Global Antimicrob Resist"},{"key":"4788_CR130","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jgar.2024.07.019","volume":"39","author":"AN Singh","year":"2024","unstructured":"Singh AN, Singh A, Nath G (2024b) Evaluation of bacteriophage cocktail on urinary tract infection caused by colistin-resistant  Klebsiella pneumoniae in mice model. J Glob Antimicrob Resist 39:41\u201353. https:\/\/doi.org\/10.1016\/j.jgar.2024.07.019","journal-title":"J Glob Antimicrob Resist"},{"key":"4788_CR131","first-page":"32","volume":"8","author":"ES Sokhn","year":"2020","unstructured":"Sokhn ES, Salami A, El Roz A, Salloum L, Bahmad HF, Ghssein G (2020) Antimicrobial susceptibilities and laboratory profiles of Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates as agents of urinary tract infection in Lebanon: paving the way for better diagnostics. Med Sci 8:32","journal-title":"Med Sci"},{"key":"4788_CR132","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2022.11.017","volume":"186","author":"SA Strathdee","year":"2023","unstructured":"Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT (2023) Phage therapy: from biological mechanisms to future directions. Cell 186:17\u201331","journal-title":"Cell"},{"key":"4788_CR133","doi-asserted-by":"publisher","first-page":"e02071","DOI":"10.1128\/aac.02071-21","volume":"66","author":"GA Suh","year":"2022","unstructured":"Suh GA et al (2022) Considerations for the use of phage therapy in clinical practice. Antimicrob Agents Chemother 66:e02071\u2013e02021","journal-title":"Antimicrob Agents Chemother"},{"key":"4788_CR134","doi-asserted-by":"publisher","first-page":"e241668","DOI":"10.1148\/radiol.241668","volume":"313","author":"PS Suh","year":"2024","unstructured":"Suh PS et al (2024) Comparing large Language model and human reader accuracy with new England journal of medicine image challenge case image inputs. Radiology 313:e241668","journal-title":"Radiology"},{"key":"4788_CR135","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1002\/anie.201606181","volume":"56","author":"KS Sunderland","year":"2017","unstructured":"Sunderland KS, Yang M, Mao C (2017) Phage-enabled nanomedicine: from probes to therapeutics in precision medicine. Angew Chem Int Ed 56:1964\u20131992","journal-title":"Angew Chem Int Ed"},{"key":"4788_CR136","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fmicb.2016.00465","volume":"7","author":"W Sybesma","year":"2016","unstructured":"Sybesma W et al (2016) Bacteriophages as potential treatment for urinary tract infections. Front Microbiol 7:465. https:\/\/doi.org\/10.3389\/fmicb.2016.00465","journal-title":"Front Microbiol"},{"key":"4788_CR137","doi-asserted-by":"publisher","unstructured":"Tan D et al (2019) Characterization of Klebsiella pneumoniae ST11 isolates and their interactions with lytic phages. Viruses 11. https:\/\/doi.org\/10.3390\/v11111080","DOI":"10.3390\/v11111080"},{"key":"4788_CR138","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00284-025-04311-0","volume":"82","author":"MK Thirugnanasambantham","year":"2025","unstructured":"Thirugnanasambantham MK, Thuthikkadu Indhuprakash S, Thirumalai D (2025) Phenotypic and genotypic characteristics of hypervirulent Klebsiella pneumoniae (hvKp): a narrative review. Curr Microbiol 82:341","journal-title":"Curr Microbiol"},{"key":"4788_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-024-01092-4","author":"MR Timm","year":"2024","unstructured":"Timm MR, Russell SK, Hultgren SJ (2024) Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics. Nat Rev Microbiol. https:\/\/doi.org\/10.1038\/s41579-024-01092-4","journal-title":"Nat Rev Microbiol"},{"key":"4788_CR141","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/microorganisms12010136","volume":"12","author":"F Valzano","year":"2024","unstructured":"Valzano F, Coda ARD, Liso A, Arena F (2024) Multidrug-resistant bacteria contaminating plumbing components and sanitary installations of hospital restrooms. Microorganisms 12:136","journal-title":"Microorganisms"},{"key":"4788_CR140","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/antibiotics9110732","volume":"9","author":"V Volozhantsev","year":"2020","unstructured":"Volozhantsev V N et al (2020) Characterization and therapeutic potential of bacteriophage-encoded polysaccharide depolymerases with \u03b2 galactosidase activity against Klebsiella pneumoniae K57 capsular type. Antibiotics 9:732","journal-title":"Antibiotics"},{"key":"4788_CR142","doi-asserted-by":"publisher","first-page":"198951","DOI":"10.1016\/j.virusres.2022.198951","volume":"322","author":"NV Volozhantsev","year":"2022","unstructured":"Volozhantsev NV et al (2022) Comparison of the therapeutic potential of bacteriophage KpV74 and phage-derived depolymerase (\u03b2-glucosidase) against Klebsiella pneumoniae capsular type K2. Virus Res 322:198951","journal-title":"Virus Res"},{"key":"4788_CR143","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.mpsur.2020.01.011","volume":"38","author":"C Walsh","year":"2020","unstructured":"Walsh C, Collyns T (2020) Pathophysiology of urinary tract infections. Surg (Oxford) 38:191\u2013196. https:\/\/doi.org\/10.1016\/j.mpsur.2020.01.011","journal-title":"Surg (Oxford)"},{"key":"4788_CR146","doi-asserted-by":"publisher","first-page":"35","DOI":"10.20517\/mrr.2025.31","volume":"4","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yu Y (2025) Phage therapy as a revitalized weapon for treating clinical diseases. Microbiome Res Rep 4:35","journal-title":"Microbiome Res Rep"},{"key":"4788_CR145","doi-asserted-by":"publisher","first-page":"e01834","DOI":"10.1128\/AEM.01834-18","volume":"84","author":"Y Wang","year":"2018","unstructured":"Wang Y et al (2018) CRISPR-Cas9 and CRISPR-assisted cytidine deaminase enable precise and efficient genome editing in Klebsiella pneumoniae. Appl Environ Microbiol 84:e01834\u2013e01818","journal-title":"Appl Environ Microbiol"},{"key":"4788_CR144","doi-asserted-by":"publisher","unstructured":"Wang G, Zhao G, Chao X, Xie L, Wang H (2020) The characteristic of Virulence, biofilm and antibiotic resistance of Klebsiella pneumoniae. Int J Environ Res Public Health 17. https:\/\/doi.org\/10.3390\/ijerph17176278","DOI":"10.3390\/ijerph17176278"},{"key":"4788_CR147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11033-025-10861-0","volume":"52","author":"Y Wang","year":"2025","unstructured":"Wang Y et al (2025) The application of the CRISPR-Cas system in Klebsiella pneumoniae infections. Mol Biol Rep 52:1\u201317","journal-title":"Mol Biol Rep"},{"key":"4788_CR149","doi-asserted-by":"publisher","unstructured":"Wu R et al (2024) Bacteriophage P2-71: a promising therapeutic against multidrug-resistant proteus mirabilis in urinary tract infections. Front Vet Sci 11. https:\/\/doi.org\/10.3389\/fvets.2024.1445264","DOI":"10.3389\/fvets.2024.1445264"},{"key":"4788_CR148","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3390\/microorganisms13081960","volume":"13","author":"P Wu","year":"2025","unstructured":"Wu P et al (2025) Advanced strategies in phage research: innovations, applications, and challenges. Microorganisms 13:1960","journal-title":"Microorganisms"},{"key":"4788_CR151","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/v10040189","volume":"10","author":"Y Xie","year":"2018","unstructured":"Xie Y, Wahab L, Gill JJ (2018) Development and validation of a microtiter plate-based assay for determination of bacteriophage host range and virulence. Viruses 10:189","journal-title":"Viruses"},{"key":"4788_CR150","doi-asserted-by":"publisher","first-page":"1645042","DOI":"10.3389\/fcimb.2025.1645042","volume":"15","author":"X Xie","year":"2025","unstructured":"Xie X et al (2025) Global epidemiology and resistance-related mutations of ceftazidime-avibactam-resistant  Klebsiella pneumoniae strains. Front Cell Infect Microbiol 15:1645042","journal-title":"Front Cell Infect Microbiol"},{"key":"4788_CR152","doi-asserted-by":"crossref","unstructured":"Xu X et al (2025) Effective treatment of refractory peritonitis caused by Klebsiella pneumoniae using personalized bacteriophage therapy in a peritoneal Dialysis patient. Case Report and Review of Published Literature","DOI":"10.21203\/rs.3.rs-6855042\/v1"},{"key":"4788_CR153","doi-asserted-by":"publisher","first-page":"e01258","DOI":"10.1128\/spectrum.01258-23","volume":"12","author":"S Yoo","year":"2024","unstructured":"Yoo S, Lee K-M, Kim N, Vu TN, Abadie R, Yong D (2024a) Designing phage cocktails to combat the emergence of bacteriophage-resistant mutants in multidrug-resistant\u2009  Klebsiella pneumoniae. Microbiol Spectr 12:e01258\u2013e01223. https:\/\/doi.org\/10.1128\/spectrum.01258-23","journal-title":"Microbiol Spectr"},{"key":"4788_CR154","doi-asserted-by":"publisher","first-page":"e01258","DOI":"10.1128\/spectrum.01258-23","volume":"12","author":"S Yoo","year":"2024","unstructured":"Yoo S, Lee K-M, Kim N, Vu TN, Abadie R, Yong D (2024b) Designing phage cocktails to combat the emergence of bacteriophage-resistant mutants in multidrug-resistant  Klebsiella pneumoniae. Microbiol Spectr 12:e01258\u2013e01223","journal-title":"Microbiol Spectr"},{"key":"4788_CR155","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.3390\/ph18111688","volume":"18","author":"Y Yue","year":"2025","unstructured":"Yue Y, Xu Z, Soteyome T, Premarathna M, Yin X, Liu J (2025) Phage encapsulation and delivery technology: a strategy for treating drug-resistant pathogenic microorganisms. Pharmaceuticals 18:1688","journal-title":"Pharmaceuticals"},{"key":"4788_CR156","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3390\/ph16121638","volume":"16","author":"B Zalewska-Pi\u0105tek","year":"2023","unstructured":"Zalewska-Pi\u0105tek B (2023) Phage therapy\u2014challenges, opportunities and future prospects. Pharmaceuticals 16:1638","journal-title":"Pharmaceuticals"},{"key":"4788_CR157","doi-asserted-by":"publisher","first-page":"14264","DOI":"10.3389\/abp.2025.14264","volume":"72","author":"B Zalewska-Pi\u0105tek","year":"2025","unstructured":"Zalewska-Pi\u0105tek B, Nag\u00f3rka M (2025) Phages as potential life-saving therapeutic option in the treatment of multidrug-resistant urinary tract infections. Acta Biochim Pol 72:14264","journal-title":"Acta Biochim Pol"},{"key":"4788_CR158","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3390\/antibiotics9060304","volume":"9","author":"B Zalewska-Pi\u0105tek","year":"2020","unstructured":"Zalewska-Pi\u0105tek B, Pi\u0105tek R (2020) Phage therapy as a novel strategy in the treatment of urinary tract infections caused by E. coli. Antibiot 9:304","journal-title":"Antibiot"},{"key":"4788_CR159","doi-asserted-by":"publisher","unstructured":"Zeng Y et al (2020) Application of phage in patients with urinary tract pandrug-resistant Klebsiella pneumoniae infection. Chin J Urol, pp 677\u2013680https:\/\/doi.org\/10.3760\/cma.j.cn112330-20200313-00190","DOI":"10.3760\/cma.j.cn112330-20200313-00190"},{"key":"4788_CR161","doi-asserted-by":"publisher","unstructured":"Zhang W et al (2024) Hybrid sequencing-based genomic analysis of Klebsiella pneumoniae from urinary tract infections among inpatients at a tertiary hospital in Beijing. Infect Drug Resist 17:1447\u20131457. https:\/\/doi.org\/10.2147\/IDR.S448253","DOI":"10.2147\/IDR.S448253"},{"key":"4788_CR160","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2174\/0113816128343976241117183624","volume":"31","author":"J Zhang","year":"2025","unstructured":"Zhang J, Chen S, Sun X, Chen S, Cheng Q (2025a) Phage therapy: a promising treatment strategy against infections caused by multidrug-resistant  Klebsiella pneumoniae. Curr Pharm Design 31:1007\u20131019","journal-title":"Curr Pharm Design"},{"key":"4788_CR162","doi-asserted-by":"crossref","unstructured":"Zhang Y, Lan W, Sun X (2025b) Phage-encoded depolymerases and endolysins as prospective strategies to combat multidrug-resistant  Klebsiella pneumoniae. Int J Biol Macromol 321:146159","DOI":"10.1016\/j.ijbiomac.2025.146159"},{"key":"4788_CR163","doi-asserted-by":"publisher","first-page":"e00607","DOI":"10.1128\/msystems.00607-24","volume":"9","author":"M Zhao","year":"2024","unstructured":"Zhao M, Li H, Gan D, Wang M, Deng H, Yang QE (2024) Antibacterial effect of phage cocktails and phage-antibiotic synergy against pathogenic  Klebsiella pneumoniae. Msystems 9:e00607\u201300624","journal-title":"Msystems"},{"key":"4788_CR164","doi-asserted-by":"publisher","first-page":"1032186","DOI":"10.3389\/fmicb.2022.1032186","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Shang J, Peng C, Sun Y (2022) Phage family classification under caudoviricetes: a review of current tools using the latest ICTV classification framework. Front Microbiol 13:1032186","journal-title":"Front Microbiol"},{"key":"4788_CR165","doi-asserted-by":"crossref","unstructured":"Zulk JJ, Patras KA, Maresso AW (2024a) The rise, fall, and resurgence of phage therapy for urinary tract infection. EcoSal Plus 12(1):eesp-0029-2023https:\/\/journals.asm.org\/doi\/full\/10.1128\/ecosalplus.esp-0029-2023","DOI":"10.1128\/ecosalplus.esp-0029-2023"},{"key":"4788_CR166","doi-asserted-by":"publisher","first-page":"eesp","DOI":"10.1128\/ecosalplus.esp-0029-2023","volume":"12","author":"JJ Zulk","year":"2024","unstructured":"Zulk JJ, Patras KA, Maresso AW (2024b) The rise, fall, and resurgence of phage therapy for urinary tract infection. EcoSal Plus 12:eesp\u20130029","journal-title":"EcoSal Plus"},{"key":"4788_CR167","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12985-020-01485-w","volume":"18","author":"F Zurabov","year":"2021","unstructured":"Zurabov F, Zhilenkov E (2021) Characterization of four virulent  Klebsiella pneumoniae bacteriophages, and evaluation of their potential use in complex phage Preparation. Virol J 18:9","journal-title":"Virol J"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-026-04788-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-026-04788-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-026-04788-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:03:01Z","timestamp":1777316581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-026-04788-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":167,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4788"],"URL":"https:\/\/doi.org\/10.1007\/s00203-026-04788-8","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"249"}}